A5101865867- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Amyotrophic Lateral Sclerosis Research
- Parkinson's Disease and Spinal Disorders
- Peripheral Nerve Disorders
- Neurogenetic and Muscular Disorders Research
- Cancer Treatment and Pharmacology
- Hereditary Neurological Disorders
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Long-Term Effects of COVID-19
- Innovations in Medical Education
- Clinical Reasoning and Diagnostic Skills
- Empathy and Medical Education
- Antifungal resistance and susceptibility
- Parkinson's Disease Mechanisms and Treatments
- Muscle Physiology and Disorders
- Pain Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Genetic Neurodegenerative Diseases
- Telemedicine and Telehealth Implementation
- Ophthalmology and Eye Disorders
- Orthopedic Surgery and Rehabilitation
- Autoimmune Neurological Disorders and Treatments
- Migraine and Headache Studies
St. Elizabeth Healthcare
2022-2025
Sisters of Providence Health System
2025
Humboldt District Hospital
2025
St. Elizabeth's Hospital
2025
St. Elizabeths Hospital
2024-2025
St. Elizabeth Hospital in Enumclaw
2024-2025
St. Elizabeth's Medical Center
2024-2025
University of Missouri
2015-2024
Cleveland Clinic Florida
2010-2024
Truven Health Analytics (United States)
2024
The etiology of acute exacerbations myasthenia gravis (MG) is not well understood and further characterization can lead to improved preventative measures. This study aims characterize factors contributing MG exacerbations.A total 127 patient charts were reviewed retrospectively (2011-2016) obtain demographics, immunizations, pharmaceutical records, each exacerbation, emergency department (ED) visits, hospitalizations, duration.There 212 requiring 106 ED visits 141 hospitalizations (average...
Multiple novel therapies have been approved for patients with myasthenia gravis. Our aim is to describe the early experience of efgartigimod use in acetylcholine receptor antibody-positive generalized gravis (AChR+ve gMG).This multicenter retrospective study included AChR+ve gMG from five major neuromuscular centers who were treated and had both pre- post-efgartigimod activities daily living (MG-ADL) scores. Information regarding MG history, concomitant treatment(s), MG-ADL other MG-specific...
The emerging field of teleneurology is delivering quality care to neurologic patients in increasingly numerous technologies and configurations. Teleneurology well-positioned address many the logistical issues neurologists their encounter today. However, formalized medical training has not caught up with this developing field, there a lack formal education concentrating on specific opportunities challenges teleneurology. Considering this, American Academy Neurology Telemedicine Work Group...
This is a brief report of patient who has refractory Myasthenia Gravis, on multiple long-term immunosuppressive therapies and contracted COVID-19 during this 2020 pandemic. She was quarantined for total 14 days recovered successfully without any complications (no myasthenia exacerbation or crisis, no related complications), with changes to her therapy. Treatment MG patients needs be tailored individual patient.
Physicians in most specialties frequently encounter patients with neurologic conditions. For non-neurologists, postgraduate education is variable and often limited, so every medical school9s curriculum must include clinical learning experiences to ensure that all graduating students have the basic knowledge skills required care for common symptoms emergencies. In nearly 20 years elapsed since development of initial American Academy Neurology (AAN)–endorsed core neurology clerkships, many...
BACKGROUND The tolerability of high-dose oral corticosteroids in patients with generalized myasthenia gravis (gMG) has not been systematically assessed. We evaluated adverse side effects (ASEs) corticosteroid treatment gMG. MATERIAL AND METHODS Retrospective analysis was conducted ASEs reported as being related to 39 gMG who were treated for ≥1 year. RESULTS Median (interquartile range [IQR]) age 60 (21) years, 53.8% women, and 66.7% aged ≤65 years. (IQR) prednisone duration 14 (2) months;...
Although established therapies are effective in most patients with generalized myasthenia gravis (gMG), some do not respond or they experience intolerable adverse events, highlighting the need for better tolerated, targeted treatment-refractory gMG.To describe real-world eculizumab acetylcholine receptor antibody-positive (AChR+) gMG.Retrospective chart review of 15 AChR+ gMG treated 12 months (900 mg/week 4 weeks then 1200 mg every 2 weeks). Outcome measures were Myasthenia...
Parkinson’s disease (PD) is the second most common progressive neurodegenerative characterized by presence of dopaminergic neuronal loss and motor disorders. PD dementia (PDD) a cognitive disorder that affects many patients. We have previously demonstrated proinflammatory role glia maturation factor (GMF) in neuroinflammation neurodegeneration AD, PD, traumatic brain injury (TBI), experimental autoimmune encephalomyelitis (EAE) human brains animal models. The purpose this study was to...
Abstract Introduction Autoantibodies to the Fibroblast Growth Factor Receptor 3 (FGFR3-AAbs) have been associated with idiopathic sensory-predominant neuropathy. The pathogenicity of FGFR3-AAbs in this disorder is unknown. Pathogenic mechanisms autoantibodies other dysimmune neuropathies commonly involve their direct binding antigens on either neurons or glia. expression FGFR3 human peripheral nervous system Therefore, as an initial step toward clarifying FGFR3-AAbs, we characterized nerve...
Among individuals with generalized myasthenia gravis (gMG), risk factors for increased severity over time are unknown. This study examined the association between demographic and clinical variables patient progression to a more severe MG Foundation of America (MGFA) classification. Data were drawn from Adelphi Real World Disease Specific Programme™, cross-sectional survey capturing retrospective data patients' medical histories. 421 individuals, 16% experienced gMG (progression higher MGFA...